查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1739285

全球结核病诊断市场

Tuberculosis Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 284 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球结核病诊断市场规模将达到 26 亿美元

全球结核病诊断市场规模预计在2024年为22亿美元，预计到2030年将达到26亿美元，2024年至2030年的复合年增长率为2.8%。作为本报告分析的细分市场之一，基于培养的诊断市场预计将以1.9%的复合年增长率增长，并在分析期结束时达到11亿美元。痰液检测市场在分析期间的复合年增长率预计为3.7%。

美国市场规模估计为 6.014 亿美元，中国市场预计复合年增长率为 5.1%

美国结核病诊断市场规模预计在2024年达到6.014亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到5.003亿美元，在2024-2030年的分析期内，复合年增长率为5.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.1%和2.0%。在欧洲，预计德国市场的复合年增长率为1.5%。

全球结核病诊断市场—主要趋势与驱动因素摘要

为什么结核病在 21 世纪仍然是诊断难题？

结核病 (TB) 儘管是一种可预防和可治癒的疾病，但它仍然是一项重大的公共卫生挑战，尤其是在中低收入国家。全球对抗结核病的最大挑战之一是及时准确地诊断结核病，尤其是在儿童、爱滋病毒感染者以及偏远和资源匮乏地区等弱势群体中。痰液涂片镜等传统方法虽然被广泛使用，但敏感度较低，尤其对于肺外结核病和潜伏性结核病。此外，培养方法的周转时间较长，而许多结核病流行地区基础设施和熟练的医务人员有限，使得先进的诊断方案难以大规模实施。结核病的临床表现多样，且与其他呼吸系统疾病的相似性使诊断更加复杂，常常导致误诊和延误治疗。这些限制凸显了我们迫切需要更快速、更准确、更方便的诊断技术，以弥合感染与治疗之间的差距。

新科技如何颠覆结核病诊断格局？

近年来，诊断技术创新蓬勃发展，旨在使结核病检测更快、更准确、更便利。分子诊断工具，尤其是像GeneXpert和Truenat这样的核酸增幅检查（NAAT），大大提高了我们在数小时内检测结核病和耐多药结核病（MDR-TB）的能力。这些即时诊断技术正在应用于野外诊所和农村卫生中心，以便在无需复杂实验室基础设施的情况下实现快速诊断。除了NAAT之外，干扰素-γ释放检测法（IGRA）和结核分枝桿菌抗原检测等突破性技术正在拓展诊断选择，尤其是在爱滋病毒感染族群和儿科环境中。人工智慧也被用于改善胸部X光片的判读，数位诊断平台正在改善检体追踪、数据记录和流行病学绘图。诊断和行动医疗解决方案的整合可以实现远距咨询、跟进和集中决策，这在结核病发病率高、卫生系统分散的国家尤其有用。

全球推动全民健康覆盖是否会影响结核病诊断的可近性？

全球迈向全民健康覆盖 (UHC) 的运动和联合国消除结核病策略正迫使各国政府和国际组织改善诊断可及性，以此作为迈向消除结核病的根本步骤。世卫组织、全球基金和国际药品采购机制等多边组织正在积极资助诊断工具的开发、采购和分发，并专注于可负担性和扩充性。各国正在敦促国家结核病计画将快速分子诊断纳入初级卫生保健中心，以使早期检测更加可行和分散。同时，官民合作关係正在兴起，旨在开发负担得起的诊断试剂套件和本地製造能力，以克服供应链瓶颈。然而，由于城乡差异和可负担性问题，诊断公平仍然是一个挑战。一些政府正在采用综合疾病检测平台，将结核病检测与爱滋病毒、新冠肺炎和肝炎筛检结合，这不仅可以提高检出率，还可以提高卫生系统的效率。预计这种多疾病检测框架将促进高风险族群中结核病的广泛诊断。

推动结核病诊断市场成长的因素是什么？

结核病诊断市场的成长受到多种因素的推动，包括全球人口密集高风险地区结核病发病率的上升、公共卫生部门在感染疾病控制方面投入的不断增加，以及分子诊断工具的快速普及。终端使用行为，例如社区诊所和行动医疗单位对即时检测的日益偏好，正在推动对可携式快速诊断工具的需求。此外，抗药性结核病菌株的出现，促使人们越来越多地采用先进的分子平台，这些平台可以同时检测抗药性标记和结核病原体。世界卫生组织和各国政府的资金支持也加速了结核病流行国家（尤其是非洲、东南亚和东欧）诊断工具的部署。多重检测、样本池和结果自动化解读等技术趋势正在进一步增强营运的扩充性。消费者行为也在发生变化，新冠疫情后，人们对结核病症状和检测措施的认识不断提高，从而更加积极主动地寻求早期诊断。

部分

类型（基于培养的诊断、痰液检测、快速分子诊断、其他类型）、最终用户（医院、诊断实验室、其他最终用户）

受访公司范例（44家值得关注的公司）

  • Abbott Laboratories
  • AdvaCare Pharma
  • Becton, Dickinson and Company（BD）
  • bioMerieux SA
  • Cepheid（Danaher Corporation）
  • DiaSorin SpA
  • FIND（Foundation for Innovative New Diagnostics）
  • F. Hoffmann-La Roche AG
  • Hain Lifescience GmbH
  • Hologic, Inc.
  • JN-International Medical Corporation
  • Lionex GmbH
  • Lupin Limited
  • Novosibirsk TB Research Institute
  • Oxford Immunotec Ltd.
  • QIAGEN NV
  • R-Biopharm AG
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP34450

Global Tuberculosis Diagnostics Market to Reach US$2.6 Billion by 2030

The global market for Tuberculosis Diagnostics estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Culture based Diagnosis, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Sputum Test segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$601.4 Million While China is Forecast to Grow at 5.1% CAGR

The Tuberculosis Diagnostics market in the U.S. is estimated at US$601.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$500.3 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Tuberculosis Diagnostics Market - Key Trends & Drivers Summarized

Why Is Tuberculosis Still a Diagnostic Challenge in the 21st Century?

Despite being a preventable and curable disease, tuberculosis (TB) continues to pose a major public health challenge, especially in low- and middle-income countries. One of the biggest hurdles in the global fight against TB is the timely and accurate diagnosis of the disease, particularly among vulnerable populations such as children, people living with HIV, and individuals in remote or under-resourced areas. Traditional methods like sputum smear microscopy, though widely used, suffer from low sensitivity, especially in cases of extrapulmonary and latent TB. Moreover, the long turnaround time associated with culture methods and the limitations in infrastructure and skilled personnel in many endemic regions make advanced diagnostic solutions difficult to implement at scale. TB's variable clinical manifestations and similarities with other respiratory illnesses further complicate diagnosis, often leading to misdiagnosis or delayed treatment. These limitations underscore the urgent need for faster, more accurate, and accessible diagnostic technologies to help bridge the gap between infection and intervention.

How Are New Technologies Disrupting the Diagnostic Landscape for TB?

Recent years have seen an explosion in diagnostic innovations aimed at making TB detection faster, more accurate, and accessible. Molecular diagnostic tools, particularly nucleic acid amplification tests (NAATs) like GeneXpert and Truenat, have significantly improved the ability to detect TB and multidrug-resistant TB (MDR-TB) within hours. These point-of-care technologies are being deployed in field clinics and rural health centers, where they allow for rapid diagnosis without the need for complex lab infrastructure. In addition to NAATs, other breakthroughs such as interferon-gamma release assays (IGRAs) and TB LAM antigen tests are expanding diagnostic options, especially for people with HIV or in pediatric settings. Artificial intelligence is also being applied to enhance chest X-ray interpretation, while digital diagnostic platforms are improving sample tracking, data recording, and epidemiological mapping. The convergence of diagnostics with mobile health solutions enables remote consultations, follow-ups, and centralized decision-making, particularly valuable in countries with high TB burdens and fragmented healthcare systems.

Is the Global Push for Universal Health Coverage Influencing TB Diagnostic Access?

The global movement toward Universal Health Coverage (UHC) and the United Nations' End TB Strategy are exerting pressure on governments and international agencies to improve diagnostic access as a fundamental step toward eradication. Multilateral organizations like the WHO, Global Fund, and UNITAID are actively funding diagnostic tool development, procurement, and distribution, with a focus on affordability and scalability. National TB programs are being urged to integrate rapid molecular diagnostics into primary healthcare centers, making early detection more feasible and decentralized. In parallel, public-private partnerships are emerging to develop affordable diagnostic kits and local manufacturing capacities to overcome supply chain bottlenecks. However, diagnostic equity remains a challenge, with urban-rural disparities and affordability issues limiting reach. Some governments are adopting integrated disease testing platforms that combine TB testing with HIV, COVID-19, and hepatitis screening, which not only enhances detection but also improves healthcare system efficiency. These multi-disease testing frameworks are expected to drive increased uptake of TB diagnostics across high-risk populations.

What Is Driving Growth in the Tuberculosis Diagnostics Market?

The growth in the tuberculosis diagnostics market is driven by several factors, including the rising global TB incidence in densely populated and high-risk regions, increasing public health investments in infectious disease management, and rapid adoption of molecular diagnostic tools. End-use behavior, such as a growing preference for point-of-care testing in community clinics and mobile health units, is pushing the demand for portable, rapid diagnostics. Additionally, the emergence of drug-resistant TB strains has led to increased adoption of advanced molecular platforms capable of detecting resistance markers alongside TB pathogens. Funding from global health bodies and national governments is also accelerating the deployment of diagnostic tools, especially in endemic countries in Africa, Southeast Asia, and Eastern Europe. Technological trends such as multiplex testing, sample pooling, and automated result interpretation are further enhancing operational scalability. Consumer behavior is also shifting, with heightened awareness about TB symptoms and testing avenues post-COVID, making individuals more proactive in seeking early diagnosis - a factor that will continue to fuel diagnostic volumes globally.

SCOPE OF STUDY:

The report analyzes the Tuberculosis Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis, Other Types); End-Use (Hospitals, Diagnostic Labs, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • AdvaCare Pharma
  • Becton, Dickinson and Company (BD)
  • bioMerieux SA
  • Cepheid (Danaher Corporation)
  • DiaSorin S.p.A.
  • FIND (Foundation for Innovative New Diagnostics)
  • F. Hoffmann-La Roche AG
  • Hain Lifescience GmbH
  • Hologic, Inc.
  • JN-International Medical Corporation
  • Lionex GmbH
  • Lupin Limited
  • Novosibirsk TB Research Institute
  • Oxford Immunotec Ltd.
  • QIAGEN N.V.
  • R-Biopharm AG
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Tuberculosis Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Adoption of Rapid Molecular Testing Platforms Drives Early Detection and Case Management
    • Increasing Focus on Drug-Resistant TB Surveillance Strengthens Market Need for Genotypic Tools
    • Integration of AI in X-Ray Screening Expands Diagnostic Reach in Resource-Limited Settings
    • Public Health Funding and Global Donor Programs Propel Growth of Point-of-Care Diagnostics
    • Shift Toward Decentralized Testing Models Drives Demand for Portable and Compact Devices
    • Rising Co-Infection with HIV Accelerates Demand for Dual and Multiplex Testing Kits
    • Government Mandates for TB Case Notification Systems Spur Diagnostic Infrastructure Investments
    • Regulatory Approvals for Novel Antigen-Based Tests Expand Testing in Pediatric Populations
    • Expansion of Mobile and Remote Diagnostic Units Sustains Outreach in Rural Areas
    • Inclusion of TB Testing in Universal Health Coverage Expands Access and Market Size
    • Digital Reporting and Sample Tracking Platforms Drive Operational Efficiency in Testing Labs
    • Demand for Cost-Effective, High-Sensitivity Tools Creates Market Entry Opportunities for Local Players
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tuberculosis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tuberculosis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Culture based Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Culture based Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Culture based Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sputum Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Sputum Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Sputum Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rapid Molecular Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rapid Molecular Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Rapid Molecular Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Tuberculosis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Tuberculosis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Tuberculosis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Tuberculosis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION